United Immunity, Co., Ltd.
Unite the Power of Immunity and Nanoparticle, Change the Future of Patients
Biotechnology Research·0 Followers
Overview
United Immunity is developing next-generation in vivo cell therapies that use its proprietary Myeloid Targeting Platform™ to selectively target disease-associated macrophages and dendritic cells, directly within the body and program them toward therapeutic functions. Our Technology The Myeloid Targeting Platform™ comprises two nanoparticle technologies based on a polysaccharide pullulan. • PNP: A pullulan nanoparticle for delivering small molecules, peptides, and proteins • P-LNP: A PEG-free, pu...See more
Website
https://unitedimmunity.co.jp/en/Industry
Biotechnology Research
Company size
17 employees
Headquarters
Tokyo
Founded
2017
Upgrade to view team
View current team members and their roles
Access founders information
Request warm introductions
Funding Rounds (1)
JPY 13,900,000 • Funding Round
Announced on 9/24/2026
Mixed financing: JPY1.8B private equity plus JPY0.4B debt.
Open Positions(0)
No open jobs posted for this organization yet.
Company Updates
No updates available yet.